About Empagliflozin API
Categoría Terapéutica Anti-diabético
Número CAS
864070-44-0
Tecnología del API
Sintética
Forma de Dosificación
Tabletas
Estado de Desarrollo en Dr. Reddy’s
Disponible
Presentación Regulatoria Disponible
USDMF, DMF de Corea, DMF de Canadá, Singapore DMF, Australia DMF, Saudi Arabia, Malaysia DMF
Mechanism of Action
Sodium-glucose co-transporter 2 (SGLT2) is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Empagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Indication
JARDIANCE is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated:
- As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,
- To reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related APIs
Dapagliflozina (amorfa)
Anti-diabético
Pioglitazona Clorhidrato
Anti-diabético
Glimepirida
Anti-diabético
Dapagliflozin (Propanediol Monohydrate)
Anti-diabético
Empagliflozin
Anti-diabético
Linagliptina (Mix of Form A and B)
Anti-diabético
Sitagliptin Phosphate (Monohydrate)
Anti-diabético
Liraglutida
Anti-diabético
Sitagliptin Phosphate (Anhydrous)
Anti-diabético
Clorhidrato De Sitagliptina
Anti-diabético
Semaglutide
Anti-diabético